Skip to Main Content

Paper Details

The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer.
Sci Rep
2
2022
Author NameAffiliation
Andrew V KossenkovCenter for Systems and Computational Biology, Wistar Institute
Himisha BeltranDana-Farber Cancer Institute and Harvard Medical School
Himisha BeltranDana-Farber Cancer Institute and Harvard Medical School
Eva CoreyUniversity of Washington
  • 1 - 4

Datasets

Release 1.2